Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 3, 2015, Pages 305-315

  Sotgiu, Giovanni ^a   Pontali, Emanuele ^b   Centis, Rosella ^c   D'ambrosio, Lia ^c   Migliori, Giovanni Battista ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

delamanid; MDR TB prevention; mycolic acid inhibition; nitro dihydro imidazooxazole; Tuberculosis

Indexed keywords

BEDAQUILINE; DELAMANID; EFAVIRENZ; ISONIAZID; LINEZOLID; LOPINAVIR PLUS RITONAVIR; PLACEBO; RIFAMPICIN; SUTEZOLID; TENOFOVIR; MYCOLIC ACID; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANEMIA; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; ASTHENIA; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLINICAL EFFECTIVENESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEADACHE; HEALTH CARE COST; HEALTH CARE POLICY; HEART PALPITATION; HEMOPTYSIS; HUMAN; HYPERHIDROSIS; HYPERURICEMIA; HYPOCALCEMIA; INCIDENCE; INSOMNIA; MALAISE; MEDICATION COMPLIANCE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PARESTHESIA; QT PROLONGATION; RETICULOCYTOSIS; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; TREATMENT DURATION; TREATMENT PLANNING; TREMOR; TUBERCULOSIS CONTROL; UPPER ABDOMINAL PAIN; VOMITING; ADULT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; EUROPE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; JAPAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); WORLD HEALTH ORGANIZATION;

ADULT; ANTITUBERCULAR AGENTS; EUROPE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; JAPAN; MYCOBACTERIUM TUBERCULOSIS; MYCOLIC ACIDS; NITROIMIDAZOLES; OXAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WORLD HEALTH ORGANIZATION;

EID: 84923009815     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1011127     Document Type: Article

References (67)

1. Sotgiu G, Mauch V, Migliori GB, Benedetti A. Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. Eur Respir J 2014;43:1563-6
2. Resolution WHA67.1. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization. 2014. Available from: http://apps.who.int/gb/ebwha/pdf-files/WHA67/A67-R1-en.pdf
3. Voniatis C, Migliori GB, Voniatis M, et al. Tuberculosis elimination: dream or reality? The case of Cyprus. Eur Respir J 2014;44:543-6
4. Sotgiu G, Migliori GB. Is tuberculosis elimination a reality? Lancet Infect Dis 2014;14:364-5
5. World Health Organization. Global tuberculosis report 2014. WHO/HTM/TB2014.08. Geneva: World Health Organization. 2014
6. World Health Organization. Towards tuberculosis elimination - an action framework for low-incidence countries. WHO/HTM/TB2014.13. Geneva: World Health Organization. 2014
7. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013;42:785-801
8. World Health Organization. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva: World health Organization. 2015
9. D'Ambrosio L, Dara M, Tadolini M, et al. TB Elimination: theory and practice in Europe. Eur Respir J 2014;43:1410-20
10. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015;in press
11. Pontali E, Matteelli A, Migliori GB. Drug-resistant tuberculosis. Curr Opin Pulm Med 2013;19:266-72
12. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report. WHO/HTM/TB/2011.3. Geneva: World Health Organization. 2011
13. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis - current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012;205(Suppl 2):S228-40
14. Migliori GB, Centis R, D'Ambrosio L, et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis 2012;54:1379-80
15. Zignol M, Dara M, Dean AS, et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. Drug Resist Updat 2013;16:108-15
16. Ulmasova DJ, Uzakova G, Tillyashayhov MN, et al. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011. Euro Surveill 2013;18:42
17. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012;39:1425-31
18. Acosta CD, Dadu A, Ramsay A, Dara M. Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward. PHA 2014;4:S3-S12
19. Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007;12(5): E070517.1
20. Udwadia Z, Vendoti D. Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining. J Epidemiol Community Health 2013;67:471-2
21. Migliori GB, Sotgiu G, Gandhi NR, et al. The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drug resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013;42:169-79
22. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9(8): e1001300
23. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013;42:156-68
24. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28
25. Diel R, Rutz S, Castell S, Schaberg T. Tuberculosis: cost of illness in Germany. Eur Respir J 2012;40:143-51
26. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013;42:252-71
27. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009;34:387-93
28. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012;16:447-54
29. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012;40:1430-42
30. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18
31. Sotgiu G, Centis R, D'Ambrosio L, et al. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013;42:288-90
32. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2014; published online 18 September 2014; doi:10.1183/09031936.00035114
33. Sotgiu G, Pontali M, Migliori GB. Linezolid to treat M/XDR-TB: available evidence and future scenarios. Eur Respir J 2015;45:25-9
34. Engohang-Ndong J. Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment. Expert Opin Investig Drugs 2012;21(12):1789-800
35. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014;44:811-15
36. Codecasa LR, Ciconali G, Mazzola E, et al. Managing an XDR-TB outbreak: the public health face of the medal. Eur Respir J 2015;45:25-9
37. Daskapan A, de Lange W.C.M, Akkerman O.W, et al.Is screening for Rifampicin drug exposure in TB-HIV co-infected patients needed? Eur Respir J 2014;in press
38. Upton AM, Cho S, Yang TJ, et al. In vitro and in vivo activity against M. tuberculosis of the nitroimidazole TBA-354. Antimicrob Agents Chemother 2014;published online 20 October 2014; doi:10.1128/AAC.03823-14
39. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44
40. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466
41. Saliu OY, Crismale C, Schwander SK, et al. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J Antimicrob Chemother 2007;60:994-8
42. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011l;15:949-54
43. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013;41:1393-400
44. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60
45. Petersen C, Paccaly A, Kim J, et al. Delamanid, a new drug for multi-drug resistant tuberculosis (MDR-TB), and efavirenz do not show clinically relevant drug interactions in healthy subjects. Abstract A-1255. ICAAC Conference 2012
46. Paccaly A, Petersen C, Patil S, et al. Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDRTB) and tenofovir or lopinavir/ritonavir in healthy subjects. 19th International AIDS Conference; Abstract no. WEPE043
47. Deltyba. Product Information. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002552/WC500166232.pdf [last accessed 0n 2 November 2014]
48. Shimokawa Y, Sasahara K, Yoda N, et al. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro. Biol Pharm Bull 2014;37(11):1727-35
49. Wells CD, Gupta R, Hittel N, Geiter LJ. Long-term Mortality Assessment of Multidrug-resistant Tuberculosis (MDRTB) Patients Treated with Delamanid. Eur Respir J 2015;in press
50. Available from: https://clinicaltrials.gov
51. Safety and efficacy trial of delamanid for 6 months in patients with multidrug resistant tuberculosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01424670
52. Acosta CD, Rusovich V, Harries AD, et al. A new roadmap for childhood tuberculosis. Lancet Glob Health 2014;2(1):e15-17
53. Stop TB Partnership Childhood TB Subgroup, World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Int J Tuberc Lung Dis 2006;10:1205-11
54. World Health Organization. Guidance for national tuberculosis programmes. on the management of tuberculosis in children. 2nd ed. WHO/HTM/TB/2014.03. Geneva: World Health Organization. 2014
55. A 6-month safety, efficacy, and pharmacokinetic trial of delamanid in pediatric patients with multidrug resistant tuberculosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01859923
56. Pharmacokinetic and safety trial to determine the appropriate dose for pediatric patients with multidrug resistant tuberculosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01856634
57. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2013.6. Geneva: World Health Organization. 2013
58. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. WHO/HTM/TB2014.23. Geneva: World Health Organization. 2014
59. D'Ambrosio L, Tadolini M, Dupasquier S, et al. ERS/WHO Tuberculosis Consilium: reporting of the initial 10 cases. Eur Respir J 2014;43:286-9
60. Blasi F, Dara M, van der Werf MJ, Migliori GB. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013;41:491-4
61. D'Ambrosio L, Tadolini M, Centis R, et al. Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. Int J Infect Dis 2015;in press
62. Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J 2014;44(6):1412-17
63. World Health Organization. WHO Policy Implementation Package for new TB drug introduction. Geneva: world Health Organization, 2014. Available at http://www.who.int/tb/PIPnewTBdrugs.pdf?ua=1
64. Sotgiu G, Gegia M, Migliori GB. Extra-pulmonary tuberculosis: the comorbidity of the near future? Int J Tuberc Lung Dis 2014;18(12):1389
65. Sandgren A, Hollo V, van der Werf MJ. Extrapulmonary tuberculosis in the European Union and European Economic Area, 2002 to 2011. Euro Surveill 2013;18:12
66. Adada H, Valley MA, Nour SA, et al. Epidemiology of extrapulmonary tuberculosis in USA: high rates persist in the post-HIV era. Int J Tuberc Lung Dis 2014;18:1516-21
67. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013;13:529-39